Subscribe

Matthew Gantz

President and chief executive officer, Castle Creek Biosciences

Articles by Matthew Gantz

Targeting Unmet Needs in Rare Dermatologic Diseases With Gene Therapy

ByMatthew Gantz

February 18th 2022

Matthew Gantz, president and chief executive officer, Castle Creek Biosciences, discussed FCX-013 for the potential treatment of scleroderma.

Matthew Gantz

Assessing Gene Therapy in Recessive Dystrophic Epidermolysis Bullosa

ByMatthew Gantz

February 1st 2022

Matthew Gantz, president and chief executive officer, Castle Creek Biosciences, discussed the company and its pipeline.

Latest Updated Articles

Assessing Gene Therapy in Recessive Dystrophic Epidermolysis Bullosa
Published: February 1st 2022 | Updated:
Targeting Unmet Needs in Rare Dermatologic Diseases With Gene Therapy
Published: February 18th 2022 | Updated:

Trending on CGTlive®

BLA for Rocket’s LAD-I Gene Therapy Under Review by FDA Again

Regeneron’s Gene Therapy DB-OTO Improves Speech Perception in Children With Otoferlin-Related Hearing Loss

Myrtelle’s Canavan Disease Gene Therapy Effects Significant Decrease in CSF NAA and Increases in Brain Myelin Volume

© 2025 MJH Life Sciences^®

All rights reserved.